Joana Briosa Neves

Joana Briosa Neves

Auto-generated profile, based on publicly available information

Joana Briosa Neves


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in European Urology
Verified
Journal Article
Closed access
VKVeeru Kasivisvanathan
Veeru Kasivisvanathan
ASArmando Stabile
Armando Stabile
JNJoana B. Neves
Joana B. Neves
FGFrancesco Giganti
Francesco Giganti
MVMassimo Valerio
Massimo Valerio
CMCaroline M. Moore
Caroline M. Moore

18 April 2016 in BMJ
Verified
Journal Article
Open access
PDF file
FRFilipe Brogueira Rodrigues
Filipe Brogueira Rodrigues
JNJoana Briosa Neves
Joana Briosa Neves
Daniel Gomes CaldeiraDaniel Gomes Caldeira
Daniel Gomes Caldeira
JFJosé M Ferro
José M Ferro
JFJoaquim J Ferreira
Joaquim J Ferreira
JCJoão Costa
João Costa
Objectives To evaluate the efficacy and safety of endovascular treatment, particularly adjunctive intra-arterial mechanical thrombectomy, in patients with ischaemic stroke. Design Systematic review and meta-analysis. Data sources Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science, SciELO, LILACS, and clinical trial registries from inception to December 2015. Reference lists were crosschecked. Eligibility criteria for selecting studies Randomised controlled trials in adults aged 18 or more with ischaemic stroke comparing endovascular treatment, including thrombectomy, with medical care alone, including intravenous recombinant tissue plasminogen activator (rt-PA). Trial endpoints were functional outcome (modified Rankin scale scores of ≤2) and mortality at 90 days after onset of symptoms. No language or time restrictions applied. Results 10 randomised controlled trials (n=2925) were included. In pooled analysis endovascular treatment, including thrombectomy, was associated with a higher proportion of patients experiencing good (modified Rankin scale scores ≤2) and excellent (scores ≤1) outcomes 90 days after stroke, without differences in mortality or rates for symptomatic intracranial haemorrhage, compared with patients randomised to medical care alone, including intravenous rt-PA. Heterogeneity was high among studies. The more recent studies (seven randomised controlled trials, published or presented in 2015) proved better suited to evaluate the effect of adjunctive intra-arterial mechanical thrombectomy on its index disease owing to more accurate patient selection, intravenous rt-PA being administered at a higher rate and earlier, and the use of more efficient thrombectomy devices. In most of these studies, more than 86% of the patients were treated with stent retrievers, and rates of recanalisation were higher (>58%) than previously reported. Subgroup analysis of these seven studies yielded a risk ratio of 1.56 (95% confidence interval 1.38 to 1.75) for good functional outcomes and 0.86 (0.69 to 1.06) for mortality, without heterogeneity among the results of the studies. All trials were open label. Risk of bias was moderate across studies. The full results of two trials are yet to be published. Conclusions Moderate to high quality evidence suggests that compared with medical care alone in a selected group of patients endovascular thrombectomy as add-on to intravenous thrombolysis performed within six to eight hours after large vessel ischaemic stroke in the anterior circulation provides beneficial functional outcomes, without increased detrimental effects. Systematic review registration PROSPERO CRD42015019340.

18 January 2016 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
JGJoana Gameiro
Joana Gameiro
JNJoana Briosa Neves
Joana Briosa Neves
NRNatacha Rodrigues
Natacha Rodrigues
CBCatarina Bekerman
Catarina Bekerman
MMMaria João Melo
Maria João Melo
JLJosé António Lopes
José António Lopes
Acute kidney injury (AKI) is frequent during hospitalization and may contribute to adverse consequences. We aimed to evaluate long-term adverse renal function and mortality after postoperative AKI in a cohort of patients undergoing major abdominal surgery. We performed a retrospective analysis of adult patients who underwent major non-vascular abdominal surgery between January 2010 and February 2011 at the Department of Surgery II of Hospital de Santa Maria–Centro Hospitalar Lisboa Norte, Portugal. Exclusion criteria were as follows: chronic kidney disease on renal replacement therapy, undergoing renal replacement therapy the week before surgery, death before discharge and loss to follow-up through January 2014. Patients were categorized according to the development of postoperative AKI in the first 48 h after surgery using the Kidney Disease: Improving Global Outcomes classification. AKI was defined by an increase in absolute serum creatinine (SCr) ≥0.3 mg/dL or by a percentage increase in SCr ≥50% and/or by a decrease in urine output to 6 h. Adverse renal outcomes (need for long-term dialysis and/or a 25% decrease in estimated glomerular filtration rate after hospital discharge) and mortality after discharge were evaluated. Cumulative mortality was analysed with the Kaplan–Meier method and log-rank test and outcome predictive factors with the Cox regression. Significance was set at P < 0.05. Of 390 selected patients, 72 (18.5%) developed postoperative AKI. The median follow-up was 38 months. Adverse renal outcomes and death after hospital discharge were more frequent among AKI patients (47.2 versus 22.0%, P < 0.0001; and 47.2 versus 20.5%, P < 0.0001, respectively). The 4 year cumulative probability of death was 44.4% for AKI patients, while it was 19.8% for patients with no AKI (log-rank test, P < 0.0001). In multivariate analysis, AKI was a risk factor for adverse renal outcomes (adjusted hazard ratio 1.6, P = 0.046) and mortality (adjusted hazard ratio 1.4, P = 0.043). AKI after major abdominal surgery was independently associated with the risk of long-term need for dialysis and/or renal function decline and with the risk of death after hospital discharge.

1 September 2019 in BJR|case reports
Verified
Journal Article
Open access
MTMaxine Tran
Maxine Tran
ALArash Latifoltojar
Arash Latifoltojar
JNJoana B. Neves
Joana B. Neves
MPMarianthi-Vasiliki Papoutsaki
Marianthi-Vasiliki Papoutsaki
FGFiona Gong
Fiona Gong
SPShonit Punwani
Shonit Punwani
Intratumoral genetic heterogeneity and the role of metabolic reprogramming in renal cell carcinoma have been extensively documented. However, the distribution of these metabolic changes within the tissue has not been explored. We report on the first-in-human in vivo non-invasive metabolic interrogation of renal cell carcinoma using hyperpolarized carbon-13 (13C) MRI and describe the validation of in vivo lactate metabolic heterogeneity against multi regional ex vivo mass spectrometry. hyperpolarized carbon-13 (13C)-MRI provides an in vivo assessment of metabolism and provides a novel opportunity to safely and non-invasively assess cancer heterogeneity.

2 March 2018 in BJU International
Verified
Journal Article
Closed access
PDF file
JNJoana B. Neves
Joana B. Neves
JWJohn Withington
John Withington
SFSarah Fowler
Sarah Fowler
PPPrasad Patki
Prasad Patki
RBRavi Barod
Ravi Barod
T(The British Association of Urological Surgeons (BAUS)
The British Association of Urological Surgeons (BAUS)

1 September 2016 in Drug Discovery Today
Verified
Journal Article
Open access
ANAgata Nyga
Agata Nyga
JNJoana Neves
Joana Neves
KSKaterina Stamati
Katerina Stamati
Marilena LoizidouMarilena Loizidou
Marilena Loizidou
MEMark Emberton
Mark Emberton
Umber CheemaUmber Cheema
Umber Cheema
The complexity of the tumour microenvironment encompasses interactions between cancer and stromal cells. Moving from 2D cell culture methods into 3D models enables more-accurate investigation of those interactions. Current 3D cancer models focus on cancer spheroid interaction with stromal cells, such as fibroblasts. However, over recent years, the cancer immune environment has been shown to have a major role in tumour progression. This review summarises the state-of-art on immunocompetent 3D cancer models that, in addition to cancer cells, also incorporate immune cells, including monocytes, cancer-associated macrophages, dendritic cells, neutrophils and lymphocytes.